clinical trial · NCT07054099
A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
Varicella (Chickenpox)Chickenpox VaccineMG1111 (Barycela inj.)VARIVAX™
brief summary
This clinical study aims to evaluate the safety and immune response of MG1111, in healthy children compared to VARIVAX. The study will follow participants for 42 days after receiving two doses, with additional follow-ups for up to 10 years to monitor varicella infection.
started
Mar 17, 2026
primary completion
Aug 1, 2027
completion
Jul 1, 2036
last updated
Apr 17, 2026
official title
A Phase III, Double-blind, Randomized, Multicenter, Multinational, Active-controlled, Non-inferiority Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol